Yesterday the Institute for Clinical and Economic Review (ICER) posted a Draft Scoping Document detailing the planned review of the comparative clinical effectiveness and value of aducanumab (Biogen) for Alzheimer’s disease. An FDA decision on aducanumab is expected in early 2021.Comments and suggested refinements meeting ICER’s formatting specifications are welcome and should be submitted by email to firstname.lastname@example.org no later than 5 PM ET on November 10, 2020.
All comments submitted must meet ICER’s formatting specifications. Additional guidance for submitting comments can be found in ICER’s Patient Participation Guide and Manufacturer Engagement Guide. ICER also welcomes submissions from stakeholders on examples of low-value care practices within this clinical area to help develop a report section on strategies to reduce waste and preserve resources for high-value, potentially higher-cost treatments.